0000950170-24-080961.txt : 20240702
0000950170-24-080961.hdr.sgml : 20240702
20240702193003
ACCESSION NUMBER: 0000950170-24-080961
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240701
FILED AS OF DATE: 20240702
DATE AS OF CHANGE: 20240702
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Michaelson Jennifer
CENTRAL INDEX KEY: 0001838061
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39856
FILM NUMBER: 241097858
MAIL ADDRESS:
STREET 1: C/O CULLINAN MANAGEMENT, INC.
STREET 2: ONE MAIN STREET SUITE 520
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cullinan Therapeutics, Inc.
CENTRAL INDEX KEY: 0001789972
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 813867811
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 1350
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-410-4650
MAIL ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 1350
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Cullinan Oncology, Inc.
DATE OF NAME CHANGE: 20210225
FORMER COMPANY:
FORMER CONFORMED NAME: Cullinan Management, Inc.
DATE OF NAME CHANGE: 20210107
FORMER COMPANY:
FORMER CONFORMED NAME: Cullinan Oncology, LLC
DATE OF NAME CHANGE: 20191001
4
1
ownership.xml
4
X0508
4
2024-07-01
0001789972
Cullinan Therapeutics, Inc.
CGEM
0001838061
Michaelson Jennifer
C/O CULLINAN THERAPEUTICS, INC.
ONE MAIN STREET, SUITE 1350
CAMBRIDGE
MA
02142
false
true
false
false
Chief Scientific Officer
false
Common Stock
2024-07-01
4
A
false
2360
9.00
A
131942
D
The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c).
In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on January 2, 2024.
/s/ Jacquelyn Sumer, Attorney-in-Fact
2024-07-02